New Three-Drug cocktail targets untreated leukemia in early trial

NCT ID NCT06514261

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether adding a drug called iadademstat to the standard combination of venetoclax and azacitidine is safe and tolerable for adults with untreated acute myeloid leukemia (AML). About 45 people with intermediate- or high-risk AML will take part. The main goal is to find the best dose and watch for side effects, while also checking how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iadademstat, venetoclax, and azacitidine
What this could lead to: If this works, it could point toward a more effective treatment for acute myeloid leukemia that hasn't been treated yet.
What could go wrong: This is a very early Phase 1 trial with only 45 people, so it's mainly checking safety and dosing. The drug combo may not work well or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Irvine, California, 92612, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.